结肠癌诊治规范课件.pptVIP

* 手术治疗是关键，淋巴结检查数量12 III期与高危II期患者需要辅助化疗 奥沙利铂在辅助化疗中有重要地位 含奥沙利铂或伊立替康方案可用于一线化疗，并可互为二线 有效药物全用到可以获得最长生存期 肝转移手术围手术期用药提倡使用FOLFOX方案 K-RAS检测有助于判断西妥昔的疗效 小 结 * * * * * 53 * * * 3 * 8 * * The QoL-data will round up the positive outcome for the EPIC trial . QoL data will be presented at ASCO 2007. * The PFS of 2.5 months for irinotecan alone shows exactly the benchmark in the previous mentioned phase III study. The addition of Erbitux improved the PFS by 54% to 4 month, which again was highly significant and resulted in an impressive hazard ratio of 0.692. Having seen this, one would expect a clear im